Kuala Lumpur, 7 April 2026 – Ekuiti Nasional Bhd (Ekuinas) has acquired a strategic minority stake in Ain Medicare Sdn Bhd, a leading Malaysian manufacturer of sterile pharmaceutical products, marking another significant move to strengthen the country’s healthcare and pharmaceutical ecosystem.
The investment, made through Ekuinas’ RM1 billion Tranche VI fund, underscores the growing importance of healthcare as a strategic sector in Malaysia’s long-term economic development.
Backing a Homegrown Pharmaceutical Leader
Ain Medicare is a well-established Bumiputera-owned pharmaceutical company specialising in sterile parenteral products, including intravenous solutions, injectables, and dialysis-related formulations.
Founded in 1993, the company operates multiple manufacturing facilities in Malaysia and serves both domestic and international markets, with exports reaching over 17 countries.
Its products are widely used in hospitals and critical care settings, making it a key player in Malaysia’s healthcare supply chain.
Strategic Investment in a High-Growth Sector
Ekuinas said the investment aligns with its mandate to scale high-potential Bumiputera enterprises in strategic industries that contribute to national resilience.
According to CEO Aliff Omar Mohamad Omar, Malaysia’s pharmaceutical industry is expected to grow at around 6.4% annually, reaching more than RM15 billion by 2030, driven by:
- Rising healthcare demand
- Ageing population
- Expansion of domestic manufacturing capabilities
This positions pharmaceuticals as a key pillar of Malaysia’s industrial transformation.
Driving Expansion and Innovation
With Ekuinas’ backing, Ain Medicare is expected to accelerate its growth strategy, focusing on:
- Expansion into specialised generics and advanced injectables
- Strengthening research and development (R&D) capabilities
- Increasing international market penetration
The company already has a strong pipeline of products and a diversified customer base, including government hospitals, private healthcare providers, and export markets.
Strengthening National Healthcare Security
The investment also reflects a broader policy shift towards healthcare self-sufficiency.
Malaysia has been increasing focus on local pharmaceutical manufacturing to:
- Reduce reliance on imports
- Enhance supply chain resilience
- Ensure availability of critical medical products
Sterile pharmaceutical products, in particular, are essential for hospital care and emergency treatment, making domestic capability strategically important.
Ekuinas Expands Its Healthcare Footprint
This deal adds to Ekuinas’ growing presence in the pharmaceutical sector.
The fund has previously invested in:
- Active pharmaceutical ingredient (API) manufacturing
- Pharmaceutical distribution
- Retail pharmacy chains
This diversified approach signals a long-term strategy to build an integrated healthcare investment ecosystem in Malaysia.
Investor Takeaway: Healthcare Emerges as Strategic Investment Theme
For investors, the transaction highlights a clear structural trend:
Healthcare and pharmaceuticals are becoming core investment themes in Malaysia’s next growth phase.
Key implications include:
- Rising institutional capital allocation into healthcare
- Strong growth outlook driven by demographics and demand
- Opportunities in high-value manufacturing and exports
As global supply chains remain volatile and healthcare demand continues to rise, investments in domestic pharmaceutical capabilities are likely to gain momentum.
In this context, Ekuinas’ move is not just a corporate transaction, it is part of a broader shift towards building a resilient, high-value healthcare economy in Malaysia.
